This policy primer explains how the FDA’s Priority Review Voucher (PRV) program works and why it is an important incentive for developing therapies for rare pediatric diseases. It also outlines the policy landscape surrounding PRV reauthorization and its impact on rare disease innovation.
New Name, Same Commitment to Rare Diseases
The EveryLife Foundation for Rare Diseases has become The RARE Foundation! Read more about our new brand and how it unifies our advocacy work on behalf of the rare disease community.
